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Available online 01 August 2016Background: Many studies investigating long-term vascular disease risk associated with hypertensive
pregnancies examined risks in relatively youngwomen amongwhom vascular disease is uncommon.We exam-
ined the prospective relation between a history of hypertension during pregnancy and coronary heart disease
(CHD) and stroke in middle-aged UK women.
Methods: In 1996–2001, 1.1 million parous women (mean age = 56 years) without vascular disease at baseline
reported their history of hypertension during pregnancy and other factors. They were followed for incident CHD
and stroke (hospitalisation or death). Adjusted relative risks (RRs) were calculated using Cox regression.
Results: Twenty-six percent (290,008/1.1 million) reported having had a hypertensive pregnancy; 27%
(79,163/290,008) of women with hypertensive pregnancy, but only 10% (82,145/815,560) of those without
hypertensive pregnancy, reported being treated for hypertension at baseline. Mean follow-up was 11.6 years
(mean ages at diagnosis/N of events: CHD = 65 years/N = 68,161, ischaemic stroke = 67 years/N = 8365,
haemorrhagic stroke = 64 years/N = 5702). Overall, the RRs (95% conﬁdence interval [CI]) of incident disease
in women with hypertensive pregnancy versus those without such history were: CHD = 1.29 (1.27–1.31),
ischaemic stroke = 1.29 (1.23–1.35), and haemorrhagic stroke = 1.14 (1.07–1.21). However, among women
with hypertensive pregnancy who were not taking hypertension treatment at baseline, their RRs (95% CI)
were onlymodestly increased: CHD=1.17 (1.14–1.19), ischaemic stroke=1.18 (1.11–1.25), and haemorrhagic
stroke = 1.09 (1.02–1.18).
Conclusion: Hypertension during pregnancy was associated with increased CHD and stroke incidence in middle
age, largely because such women also had hypertension in their 50s and 60s, which has a substantially greater
effect on vascular disease risk than hypertension during pregnancy without hypertension later in life.
© 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Keywords:
Hypertension
Hypertensive pregnancy
Women
Coronary heart disease
Stroke1. Introduction
Hypertension during pregnancy is an important cause of morbidity
andmortality in both themother and her offspring during the perinatal
period [1–3]. Its effect on the mother's vascular health has been
reported to extend for many years after the pregnancy [4–16], but
many studies have been in relatively young women among whom
vascular disease rates are still relatively low [17,18]. There is limited in-
formation on the impact of hypertension in pregnancy on the vascular
health of women in middle age [7,10,12,15,16] when vascular diseasey), ben.cairns@ceu.ox.ac.uk
cy.wright@ceu.ox.ac.uk
al@ceu.ox.ac.uk (V. Beral),
k (G. Reeves).
ity and freedom from bias of the
land Ltd. This is an open access articlrates are relatively high [17,18] and unhealthy lifestyles and other
factors, such as bodymass index, diabetes, dyslipidaemia, andhyperten-
sion, become important determinants of coronary heart disease
and stroke in the population [19,20]. Furthermore, separate risks
for ischaemic and haemorrhagic strokes remain unclear. We studied
the relationship between a history of hypertension during pregnancy
and subsequent risks of coronary heart disease and ischaemic and
haemorrhagic stroke in a cohort of over a million UK women. We
explored these associations inmiddle-agedwomen, taking into account
their health and lifestyle and other risk factors of vascular disease.
2. Methods
The Million Women Study is a population-based prospective study which recruited
1.3 million UK women aged 50 to 64 years who were invited to routine breast cancer
screening programmes of the National Health Service (NHS) in England and Scotland
from 1996 to 2001. The study design and recruitment have been described in detail
previously (www.millionwomenstudy.org) [21]. At recruitment, women ﬁlled in ae under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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height, lifestyle, and socio-economic indicators. The study population included about 1
in 4 of all UKwomenaged50 to 64 years at the time of recruitment. Participants gavewrit-
ten consent to take part in the study and the Oxford and Anglia Multi-Centre Research
Ethics Committee gave ethical approval to the study. We linked with NHS data sources
for hospital admissions and mortality to obtain information on hospitalisations and vital
status for the whole cohort [22,23]. The NHS hospital admissions data for in- and
day-patients have been obtained through linkage with the Hospital Episode Statistics
[24] for participants in England and the Scottish Morbidity Records [25] for participants
in Scotland. Hospital diagnoses and causes of death are reported to the study coded to
the World Health Organization's International Classiﬁcation of Diseases, Tenth Revision
(ICD-10) [26].
At recruitment (baseline for this study), women reported whether or not they ever
had high blood pressure during pregnancy, and whether or not they were currently
using any medication for selected conditions including hypertension, diabetes, and
hypercholesterolaemia. Taking medications particularly for hypertension is a proxy
measure for having had a clinically relevant elevation of blood pressure.Women provided
information on reproductive factors including age at menarche, parity, and use of
hormone replacement therapy. They also reported their smoking habits, alcohol
consumption, frequency of strenuous physical activity, and socioeconomic status,
as well as their weight and height, from which we calculated body mass index (BMI)
(weight in kg/[height in m]2).
We deﬁned incident vascular disease as the ﬁrst hospital admissionwith anymention
of vascular disease, or, where there was no relevant hospital admission, death with the
vascular disease as the underlying cause. We identiﬁed a ﬁrst vascular disease outcome
separately for coronary heart disease (ICD-10: I20 to I25), cerebrovascular disease
(ICD-10: I60 to I69), ischaemic stroke (ICD-10: I63), and haemorrhagic stroke (ICD-10:
I60 to I62). Virtually all residents in the United Kingdom are registered with general
practitioners who hold comprehensive information about an individual's health and
medical care in the NHS. We previously reported that there was excellent agreement
between vascular disease diagnoses recorded in hospital records and those ascertained
from the reports of general practitioners [27].
In a resurvey of the cohort about nine years after baseline recruitment, a randomly
selected subgroup of women (N = 16,954) provided non-fasting blood samples for lipid
proﬁle assessment. Details of blood sample collection, storage and lipid assays have
been reported previously [28]. Among this subgroup, some women (N = 3694) also had
their blood pressure measured at local general practices.
2.1. Statistical analysis
Of the 1.3 million women recruited to the study, we excluded 120,905 (8.9%) who
reported or had a hospital record of heart disease, stroke or cancer (except non-
melanoma skin cancer) before recruitment. Of the remaining 1.2 million women, we
further excluded 135,667 (9.9%) who were nulliparous and 2082 (0.2%) with missing
data on parity. Data for 1,105,568 parous women with information on hypertension
during pregnancy formed the basis of our analysis. We estimated hazard ratios, hereafter
referred to as relative risks, of vascular disease incidence and mortality using Cox
regression with age as the underlying time variable. Person-years were calculated from
the date of recruitment until date of ﬁrst hospitalisation, death, emigration and other
loss to follow-up, or end of follow-up for this analysis (31 March 2011 in England and
31 December 2008 in Scotland), whichever came ﬁrst. Around 5% of participants in
England were recruited before 1 April 1997. Because hospital admissions data prior to
this date were not available, we calculated their follow-up from this date.
All regressionmodelswere stratiﬁedby geographical region of recruitment (10UK re-
gions), and the covariates included bodymass index (b20, 20 to 24.9, 25 to 29.9, 30 to 34.9
and ≥35 kg/m2), smoking (never smokers, past smokers, and current smokers of b5, 5 to 9,
10 to 14, 15 to 19, 20 to 24 and ≥25 cigarettes per day), socioeconomic status (ﬁfths of
Townsend index of deprivation [29]), frequency of strenuous exercise (rarely/never,
once a week or less, and more than once a week), weekly alcohol intake (0, 1 to 6, 7 to
14 and ≥15 units), parity (1, 2, 3, 4, and ≥5 children), ever use of hormone replacement
therapy (yes or no), and treatment for diabetes (yes vs no), hypercholesterolaemia
(yes vs no), and hypertension (yes vs no) at baseline recruitment. Women with missing
values for an adjustment variable were assigned to a separate category for that
speciﬁc variable.
We calculated relative risks separately for each incident vascular disease outcome for
all women and by women's use of anti-hypertensive medication at baseline. We also
calculated the risks of death attributed to coronary heart disease and cerebrovascular
disease. To examine further the consistency of the risks across different subgroups in the
population, we examined the risks of incident coronary heart disease and stroke across a
range of characteristics at baseline (socioeconomic status, parity, smoking, body mass
index, vigorous exercise frequency, alcoholic beverage intake, hormone replacement
therapy use, treatment for diabetes, and treatment for hypercholesterolaemia at baseline).
For women with blood pressure readings and those with lipid proﬁle data measured at
around nine years after recruitment, we calculated the age- and region-adjusted mean
systolic and diastolic blood pressure, as well as cholesterol and lipid fraction concentra-
tions, according to women's history of hypertension during pregnancy and use of
anti-hypertensive medication at baseline.
We report relative riskswith their conventional 95% conﬁdence intervals (CIs). When
relative risks for multiple groups are presented (such as when estimating relative risks by
joint categories of hypertension during pregnancy and being treated for hypertension inmiddle age), we report estimates with their 95% group-speciﬁc CIs [30] to allow direct
comparison of risks between any two categories even if neither is the reference group.
We examined heterogeneity in the associations of coronary heart disease and stroke
across women's characteristics using likelihood ratio tests.
We used Stata 14.0 [31] programme to analyse our data, and used Jasper package
version 2-210 [32] in R programme [33] to create the ﬁgure.
3. Results
In this analysis of 1.1 million parous women, the mean age at
recruitment was 56.0 (SD = 4.8) years, and 26.2% (N = 290,008)
reported that they had high blood pressure during pregnancy. Table 1
shows the characteristics of the participants at baseline. By far, the
largest difference between those with and without history of hyperten-
sion during pregnancy was the proportion that reported being treated
for hypertension at recruitment in their mid-50s: 27% (79,163 of
290,008) of those with a history of hypertensive pregnancy versus
10% (82,145 of 815,560) of those without such a history were on
anti-hypertensive medication at recruitment.
Women were followed for 11.6 years (SD = 2.3 years) on average,
accruing 12.8 million person-years of follow-up. Over this time period,
68,161 women had a ﬁrst coronary disease event, 22,997 women a
cerebrovascular disease, 8365 women an ischaemic stroke, and 5702
women a haemorrhagic stroke, with mean ages at ﬁrst disease
event of 65.0 (SD = 6.1), 66.2 (SD = 6.6), 66.9 (SD = 6.4) and 64.2
(SD = 6.6) years, respectively. Of these ﬁrst vascular disease events,
non-fatal hospital admissions accounted for 92% of coronary heart
disease, 88% of cerebrovascular disease, 94% of ischaemic stroke,
and 79% of haemorrhagic stroke. There were in total 7736 deaths
attributed to coronary heart disease and 5554 to cerebrovascular
disease, with mean ages at death of 65.9 (SD = 6.5) and 66.9
(SD = 7.3) years, respectively.
Compared to women without hypertension during pregnancy, the
relative risk of a ﬁrst coronary heart disease event for women with
hypertensive pregnancy was 1.29 (95% CI 1.27 to 1.31) (Table 2). For
coronary heart disease mortality, the relative risk was 1.35 (95% CI
1.29 to 1.42). The relative risks of a ﬁrst cerebrovascular disease event
or death due to this condition were also increased in women with hy-
pertensive pregnancy. The risks of both ischaemic and haemorrhagic
stroke were increased in women with hypertensive disease during
pregnancy, with the relative risk of ischaemic stroke (1.29 [95% CI 1.23
to 1.35]) being slightly greater than the relative risk of haemorrhagic
stroke (1.14 [95% CI 1.07 to 1.21]).
Fig. 1 shows the relative risks of incident coronary heart disease and
stroke across a number of subgroups as deﬁned by the characteristics of
women at recruitment. In all the subgroups, the risks of incident
coronary heart disease and ischaemic stroke were consistently elevated
in women with a history of hypertension during pregnancy. However,
for incident coronary heart disease, the risks were somewhat weaker
among women being treated for hypercholesterolaemia or diabetes.
Nevertheless, these risks remained signiﬁcantly elevated. We also
observed a small increase in haemorrhagic stroke risks across various
subgroups with no signiﬁcant heterogeneity across any subgroup.
As many women who reported a history of hypertension during
pregnancy also reported being treated for hypertension at baseline,
we compared the risks in women categorised into subgroups as deﬁned
by these factors (Table 3). Compared with women with no history of
hypertension in pregnancy or in middle age, at study baseline, women
who reported treatment for hypertension (but no history of
hypertension in pregnancy) had substantially raised subsequent
risks of coronary heart disease (relative risk = 1.61 [95% CI 1.59 to
1.64]), of ischaemic stroke (relative risk = 1.77 [95% CI 1.69 to 1.86]),
and of haemorrhagic stroke (relative risk = 1.60 [95% CI 1.50
to 1.71]). By contrast, only modest increases in risks were seen in
women who had hypertension in pregnancy but not in middle age
(relative risks [95% CI] for coronary heart disease, ischaemic and
haemorrhagic stroke: 1.17 [1.14 to 1.19], 1.18 [1.11 to 1.25], and 1.09
Table 1
Characteristics of parous women, by reported history of hypertension during pregnancy.
Hypertension during pregnancy
All parous women
N = 1,105,568
No
N = 815,560
Yes
N = 290,008
Characteristics at baseline
Age (years), mean (SD) 56.0 (4.8) 55.9 (4.7) 56.0 (4.8)
Body mass index (kg/m2), mean (SD) 25.8 (4.4) 27.3 (5.1) 26.2 (4.6)
Age at menarche (years), mean (SD) 13.1 (1.6) 12.8 (1.6) 13.0 (1.6)
Parity, mean (SD) 2.4 (1.0) 2.4 (1.1) 2.4 (1.0)
% Current smoker (N) 21.9 (168,229) 17.6 (47,952) 20.8 (216,173)
% Non-drinker of alcoholic beverages (N) 28.9 (187,388) 30.3 (69,220) 29.3 (256,608)
% Engage in vigorous exercise ≤1 per week (N) 47.9 (376,209) 48.2 (134,897) 48.0 (511,106)
% Lowest third of socioeconomic status (N) 32.8 (265,143) 32.4 (93,354) 32.7 (358,497)
% Ever use of hormone replacement therapy (N) 51.4 (414,502) 49.7 (142,411) 51.0 (556,913)
% Being treated for hypertension (N) 10.1 (82,145) 27.3 (79,163) 14.6 (161,308)
% Being treated for diabetes (N) 1.7 (14,164) 3.0 (8646) 2.1 (22,810)
% Being treated for hypercholesterolaemia (N) 2.3 (18,552) 3.5 (10,126) 2.6 (28,678)
Follow-up details
First vascular disease event (ICD-10), no. (person-years [1000s])
Coronary heart disease (I20 to I25) 46,580 (9449) 21,581 (3333) 68,161 (12,782)
Cerebrovascular disease (I60 to I69) 16,226 (9600) 6771 (3408) 22,997 (13,008)
Ischaemic stroke (I63) 5784 (9635) 2581 (3422) 8365 (13,057)
Haemorrhagic stroke (I60 to I62) 4164 (9641) 1538 (3426) 5702 (13,067)
Underlying cause of death (ICD-10), no. (person-years [1000s])
Coronary heart disease (I20 to I25) 5216 (11,850) 2520 (4219) 7736 (16,068)
Cerebrovascular disease (I60 to I69) 4032 (11,850) 1522 (4219) 5554 (16,068)
ICD-10— International Classiﬁcation of Diseases, 10th Revision.
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both in pregnancy and in middle age had risks either similar to
(haemorrhagic stroke) ormodestly higher than (coronary heart disease
and ischaemic stroke) those for hypertension in middle age alone.
Similar patterns of risk of vascular deaths were seen across these
subgroups (Table 4).
In women with information on blood pressure measured around
nine years after recruitment (N = 3694), systolic blood pressure
and diastolic blood pressure were both elevated in women with hy-
pertension in pregnancy, whether or not they reported being treated
for hypertension at study baseline (Table 5). In women with lipid
proﬁle assessment (N = 18,104), mean plasma concentrations of
both total and HDL-cholesterol, as well as apolipoprotein B and A1,
were lowest in women who were taking anti-hypertensive medica-
tion at baseline (Web-only supplementary Table A). For those who
were not on anti-hypertensive treatment, those with a history of hy-
pertension during pregnancy had lower total and HDL-cholesterol,
as well as apolipoprotein B and A1, concentrations than those with-
out such history.Table 2
Relative risks (95% conﬁdence interval) of vascular disease in parous women, by reported hist
Vascular disease (ICD-10) No. with vascular disease ou
Hypertension during pregn
Yes
N = 290,008
First vascular disease event
Coronary heart disease (I20 to I25) 21,581
Cerebrovascular disease (I60 to I69) 6771
Ischaemic stroke (I63) 2581
Haemorrhagic stroke (I60 to I62) 1538
Underlying cause of death
Coronary heart disease (I20 to I25) 2520
Cerebrovascular disease (I60 to I69) 1522
ICD-10 — International Classiﬁcation of Diseases, 10th Revision; relative risks based on Cox r
recruitment, and adjusted for smoking, socioeconomic status, exercise, alcohol intake, body m
treatment for hypercholesterolaemia at baseline.4. Discussion
In this large cohort of middle-aged women, hypertension during
pregnancy was associated with subsequent increase in risk of vascular
disease incidence and mortality. The risks were increased for both
coronary heart and cerebrovascular disease, and the risk of stroke was
somewhat higher for ischaemic than for haemorrhagic stroke. However,
many of these women with a history of hypertensive pregnancy were
also being treated for hypertension in their 50s and 60s, and the
association with vascular disease risk was substantially greater for
being hypertensive in middle age than for having a history of hyperten-
sion during pregnancy alone.
Hypertensive disorders in pregnancy are important causes of
morbidity and mortality to the mother during the perinatal period
[1,2,34,35]. Moreover, mothers with pregnancies complicated by
hypertension, such as gestational hypertension or pre-eclampsia,
have been reported to have higher risks of later coronary
heart [4–6,8–16] and cerebrovascular disease [5,7,9–13,16] than
women with normotensive pregnancies, but many of these studiesory of hypertension during pregnancy.
tcome Relative risk (95% conﬁdence interval)
ancy
No
N = 815,560
46,580 1.29 (1.27 to 1.31)
16,226 1.23 (1.20 to 1.27)
5784 1.29 (1.23 to 1.35)
4164 1.14 (1.07 to 1.21)
5216 1.35 (1.29 to 1.42)
4032 1.16 (1.09 to 1.23)
egression with age as the underlying time variable; risk estimates stratiﬁed by region of
ass index, parity, ever use of hormone replacement therapy, treatment for diabetes, and
1.0 1.2 1.4 1.6
RR (95% g−sCI)
1.33 (1.29, 1.36)
1.26 (1.24, 1.29)
1.29 (1.27, 1.32)
1.29 (1.26, 1.32)
1.29 (1.26, 1.31)
1.27 (1.24, 1.32)
1.33 (1.29, 1.37)
1.29 (1.27, 1.32)
1.27 (1.24, 1.30)
1.33 (1.29, 1.36)
1.27 (1.23, 1.30)
1.31 (1.28, 1.34)
1.30 (1.27, 1.33)
1.29 (1.26, 1.32)
1.30 (1.28, 1.32)
1.19 (1.12, 1.26)
1.30 (1.28, 1.32)
1.16 (1.09, 1.24)
1.29 (1.27, 1.31)
RR (95% g−sCI)
CORONARY HEART DISEASE (I20 TO I25)
1.0 1.2 1.4 1.6
RR (95% g−sCI)
1.30 (1.21, 1.40)
1.28 (1.20, 1.36)
1.27 (1.19, 1.36)
1.31 (1.22, 1.41)
1.28 (1.21, 1.36)
1.26 (1.15, 1.37)
1.38 (1.27, 1.49)
1.22 (1.15, 1.30)
1.26 (1.18, 1.34)
1.32 (1.23, 1.43)
1.28 (1.18, 1.39)
1.29 (1.22, 1.37)
1.29 (1.21, 1.37)
1.29 (1.20, 1.38)
1.28 (1.22, 1.35)
1.37 (1.15, 1.62)
1.29 (1.23, 1.36)
1.21 (0.97, 1.50)
1.29 (1.23, 1.35)
RR (95% g−sCI)
ISCHAEMIC STROKE (I63)
1.0 1.2 1.4 1.6
RR (95% g−sCI)
1.13 (1.04, 1.24)
1.14 (1.05, 1.24)
1.12 (1.04, 1.21)
1.16 (1.05, 1.27)
1.16 (1.08, 1.25)
1.07 (0.96, 1.19)
1.21 (1.10, 1.32)
1.08 (0.99, 1.17)
1.08 (1.00, 1.18)
1.20 (1.10, 1.31)
1.07 (0.95, 1.20)
1.16 (1.08, 1.24)
1.12 (1.03, 1.22)
1.15 (1.06, 1.26)
1.14 (1.07, 1.21)
1.18 (0.84, 1.65)
1.13 (1.07, 1.20)
1.29 (0.95, 1.76)
1.14 (1.07, 1.21)
RR (95% g−sCI)
HAEMORRHAGIC STROKE (I60 TO I62)
Characteristics
  High
  Low
  1 to 2
  3 or more
  No
Yes
  <25
  25 or higher
  Rarely/Never
  Once a week or more
  No
Yes
  No
Yes
  No
Yes
  No
Yes
ALL WOMEN
Socioeconomic status
Parity
Current smokers
Body mass index (kg/m²)
Engage in strenuous
exercise
Alcohol beverage
drinker
Ever use of hormone 
treatment
Diabetes treatment
at baseline
Hypercholesterolemia 
treatment at baseline
No
18,755
27,825
26,446
20,134
29,147
14,685
17,532
26,107
25,909
18,209
15,244
30,694
21,035
24,693
43,951
2629
44,205
2375
46,577
Yes
9015
12,566
11,581
10,000
14,797
5444
5862
14,367
11,673
8824
7130
14,212
10,114
11,154
19,750
1831
20,099
1482
21,574
No
2374
3410
3347
2437
3462
1986
2334
3076
3208
2241
1815
3896
2993
2683
5472
310
5564
220
5784
Yes
1090
1491
1392
1189
1706
702
793
1575
1400
1035
830
1720
1374
1156
2339
242
2441
140
2581
No
1886
2278
2629
1535
2418
1576
2073
1833
2212
1764
1815
3012
2063
2032
4073
91
4054
110
4164
Yes
701
837
918
620
1016
456
624
826
774
696
830
1127
765
747
1479
59
1470
68
1538
Heterogeneity: χ1
2
=7.9 (p=0.005)
Heterogeneity: χ1
2
=0.1 (p=0.7)
Heterogeneity: χ1
2
=0.3 (p=0.6)
Heterogeneity: χ1
2
=2.8 (p=0.09)
Heterogeneity: χ1
2
=6.7 (p=0.01)
Heterogeneity: χ1
2
=3.5 (p=0.06)
Heterogeneity: χ1
2
=0.1 (p=0.8)
Heterogeneity: χ1
2
=8.2 (p=0.004)
χ1
2
=10.3 (p=0.001)
χ1
2
=0.2 (p=0.7)
χ1
2
=0.4 (p=0.5)
χ1
2
=0.1 (p=0.7)
χ1
2
=5.2 (p=0.02)
χ1
2
=1.1 (p=0.3)
χ1
2
=0.1 (p=0.8)
χ1
2
=0.0 (p=1.0)
χ1
2
=0.5 (p=0.5)
χ1
2
=0.4 (p=0.5)
χ1
2
=0.0 (p=0.9)
χ1
2
=0.2 (p=0.6)
χ1
2
=1.6 (p=0.2)
χ1
2
=3.4 (p=0.1)
χ1
2
=2.8 (p=0.1)
χ1
2
=1.3 (p=0.2)
χ1
2
=0.3 (p=0.6)
χ1
2
=0.0 (p=0.8)
χ1
2
=0.7 (p=0.4)
Hypertension during
pregnancy (No. of events)
Hypertension during
pregnancy (No. of events)
Hypertension during
pregnancy (No. of events)
Fig. 1. Relative risks (95% group-speciﬁc conﬁdence interval) of incident coronary heart disease, ischaemic stroke, and haemorrhagic stroke in parouswomenwith reported hypertension
during pregnancy (N = 290,008) as compared to women without such history (N = 815,560), by their characteristics at baseline. Relative risks are hazard ratios estimated using Cox
regression with age as the underlying time variable, stratiﬁed by region of recruitment, and adjusted for all listed factors except when the characteristic is under consideration. The
area of the square is inversely proportional to the variance of the log risk. RR — relative risk; g-sCI — group-speciﬁc conﬁdence interval; ICD-10 — International Classiﬁcation of
Diseases, 10th Revision.
Table 3
Relative risk (95% group-speciﬁc conﬁdence interval [g-sCI]) of incident coronary heart
disease and stroke in parous women, by reported history of hypertension during
pregnancy and treatment for hypertension at baseline.
Incident vascular
disease
(ICD-10)
Hypertension
during
pregnancy
Being treated for
hypertension
at baseline
No. with
outcome
Relative
risk
(95% g-sCI)
Coronary heart disease (I20 to I25)
No No 33,884 1.00 (0.99 to 1.01)
Yes No 8999 1.17 (1.14 to 1.19)
No Yes 12,696 1.61 (1.59 to 1.64)
Yes Yes 12,582 1.78 (1.76 to 1.82)
Ischaemic stroke (I63)
No No 4077 1.00 (0.97 to 1.03)
Yes No 1056 1.18 (1.11 to 1.25)
No Yes 1707 1.77 (1.69 to 1.86)
Yes Yes 1525 1.86 (1.76 to 1.96)
Haemorrhagic stroke (I60 to I62)
No No 3184 1.00 (0.96 to 1.04)
Yes No 760 1.09 (1.02 to 1.18)
No Yes 980 1.60 (1.50 to 1.71)
Yes Yes 778 1.48 (1.38 to 1.59)
ICD-10 — International Classiﬁcation of Diseases, 10th Revision; relative risks are hazard
ratios estimated using Cox regression with age as the underlying time variable, stratiﬁed
by region of recruitment, and adjusted for smoking, socioeconomic status, exercise,
alcohol intake, body mass index, parity, ever use of hormone replacement therapy, treat-
ment for diabetes, and treatment for hypercholesterolaemia at baseline; reference group:
no history of hypertensive pregnancy and not on anti-hypertensive treatment at baseline.
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(Web-only supplementary Tables B and C, and Figs. A and B), when
vascular disease is still relatively uncommon [17,18]. Compared to
women aged 30–49 years in Europe, mortality rates for vascular
disease are reported to be three times higher at age 50–59 years,
twenty times higher at 60 to 69 years, and 300 times higher at age
≥70 years [17]. This pattern is similarly seen in the US [18]. Although
a number of studies have investigated associations between hyper-
tensive disorders during pregnancy and vascular outcomes at around
middle age [7,10,12,15,16] the numbers of disease events were
relatively small (Web-only supplementary Tables B and C, and Figs.
A and B), and the contribution of other risk factors at that age was
not examined in detail. In our study, we have shown that in middle
age, a history of hypertension during pregnancy is associated with
increased coronary heart disease and stroke risks, and these associa-
tions are independent of concurrent lifestyle factors and other
potential confounders. Our ﬁndings are broadly consistent with
other studies that showed elevated risks not just for coronary heart
disease but also for cerebrovascular disease in women with hyper-
tensive pregnancies [5,7,9–13,16]. Although one study reported
ﬁndings based on few ischaemic stroke events [15], the long-term
risk of haemorrhagic stroke has not been previously reported.
In our study, we showed that both ischaemic and haemorrhagic
stroke risks are increased in women with hypertension in pregnancy
albeit the magnitude of the risk particularly of haemorrhagic stroke
was quite small.
Table 4
Relative risk (95% group-speciﬁc conﬁdence interval [g-sCI]) of coronary heart and
cerebrovascular disease mortality in parous women, by reported history of hypertension
during pregnancy and treatment for hypertension at baseline.
Underlying
cause of death
(ICD-10)
Hypertension
during
pregnancy
Being treated for
hypertension
at baseline
No. with
outcome
Relative risk
(95% g-sCI)
Coronary heart disease (I20 to I25)
No No 3582 1.00 (0.97 to 1.04)
Yes No 967 1.23 (1.16 to 1.31)
No Yes 1634 1.86 (1.77 to 1.96)
Yes Yes 1553 2.02 (1.92 to 2.14)
Cerebrovascular disease (I60 to I69)
No No 2848 1.00 (0.96 to 1.04)
Yes No 658 1.10 (1.02 to 1.18)
No Yes 1184 1.88 (1.78 to 1.99)
Yes Yes 864 1.69 (1.58 to 1.81)
ICD-10 — International Classiﬁcation of Diseases, 10th Revision; relative risks are hazard
ratios estimated using Cox regression with age as the underlying time variable, stratiﬁed
by region of recruitment, and adjusted for smoking, socioeconomic status, exercise,
alcohol intake, body mass index, parity, ever use of hormone replacement therapy, treat-
ment for diabetes, and treatment for hypercholesterolaemia at baseline; reference group:
no history of hypertensive pregnancy and not on anti-hypertensive treatment at baseline.
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pregnancy are at increased risk of high blood pressure many years
after the index pregnancy [4,36]. Our ﬁndings suggest that this relation
persists intomiddle age, and couldmediate the relation between hyper-
tension during pregnancy and long-term vascular disease risk. For
example, the relative risk of coronary heart disease associated with hy-
pertension during pregnancy was 1.29 (95% CI 1.27 to 1.31) (Table 2)
compared to those without such history. However, the relative risk
was only modestly increased 1.17 (95% CI 1.14 to 1.19) in women
with hypertension during pregnancy who were not on hypertension
treatment at baseline (Table 3), suggesting that the risk associated
with hypertension during pregnancy appears to be largely explained
byhypertension inmiddle age. Dyslipidaemiamay also play amediating
role [37,38], but the patterns of cholesterol and apolipoprotein concen-
trations in our cohort do not seem to concur with the observed vascular
disease risk estimates with hypertension during pregnancy and being
treated for hypertension at study baseline. It is plausible that, at least
in our cohort, hypertension appears to play a more important role
than dyslipidaemia in mediating the excess vascular disease risk
associated with hypertension during pregnancy.
4.1. Limitations
Our study relied on women reporting at the time of their recruit-
ment any hypertension during pregnancy. Although maternal recall of
such obstetric history has been reported to have high speciﬁcity, the
sensitivity is low [39]. In our cohort, a relatively high proportion
(26.2%) reported to have ever had high blood pressure during pregnan-
cy thanmight be expected from the prevalence of clinically-deﬁned hy-
pertensive disorders of pregnancy. Our estimate could reﬂect the
prevalence of hypertension during pregnancy throughout women's
reproductive life as well as hypertensive pregnancies without the clini-
cal features associated with conditions as gestational hypertension or
pre-eclampsia. In the prospective Northern Finland Birth Cohort 1966Table 5
Mean blood pressure (95% conﬁdence interval [CI]) at resurvey in 3694 women, by reported h
Hypertension during
pregnancy
Being treated for hypertension
at baseline
No. of
women
Me
at r
No No 2636 132
Yes No 631 137
No Yes 247 139
Yes Yes 180 139
Mean blood pressure adjusted for age at blood pressure measurement and region of recruitmestudy (involving N96% expected births in the area), mothers have had
their blood pressure measured during maternity clinic visits (93%
attended N5 times) [15]. Findings from this study suggest that while
the proportions of pre-eclampsia (≈2%) and gestational hypertension
(≈8%) were low, the proportion of new-onset hypertension which
did not meet the clinical criteria for these disorders was ≈15%, and
these phenotypes were shown to be associated with long-term risk of
cardiovascular disease. Overall, Männistö and colleagues reported that
the proportion of hypertension during pregnancy in their cohort was
≈25% (≈32% if including chronic hypertension). Although we could
not rule out recall bias, the proportion of women with hypertension
during pregnancy in our study is probably not implausible.
We also did not examine vascular disease risk in relation to speciﬁc
types of hypertensive disorders in pregnancy as such information was
not available. These different types may have varying effect sizes, with
more severe forms likely to be associated with greater magnitude of
vascular disease risk [4], so our risk estimates may underestimate the
actual risks associated with some of these speciﬁc hypertensive disor-
ders in pregnancy. It is also possible that some of the vascular disease
events which occurred prior to study participation may be related to
hypertension during pregnancy. However, differential reporting of
obstetric history may exist between those with and without prevalent
vascular disease so we excluded those with known vascular disease at
baseline from the analysis. We adjusted for a number of potential
confounders, but as an observational study, we could not rule out
residual confounding. Nevertheless, our study is based on a large
number of vascular disease events, including stroke events according
to subtype, allowing us to examine in detail the associations with
different vascular disease phenotypes at ages when the vascular disease
burden in women is high.4.2. Conclusion
In this large cohort of middle-aged women, hypertension during
pregnancywas associatedwith increased risks of coronary heart disease
and stroke. However, the risk of vascular disease associated with being
hypertensive in middle age was greater than that associated with a
history of hypertension during pregnancy alone. Since many of the
women with a history of hypertension during pregnancy were also
hypertensive in their 50s and 60s, the associations between history of
hypertensive pregnancy with coronary heart disease and stroke are
likely to be explained by increased blood pressure in middle age.
Controlling hypertension is likely to be beneﬁcial to middle-aged
women, including those with hypertension during pregnancy. But
efforts to prevent women with hypertensive pregnancy from develop-
ing hypertension bymiddle agemay be just as important to help reduce
their risk of developing vascular disease in the long-term.Funding source
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